- Supported exchanges /
- AU /
- PER.AU
Percheron Therapeutics Limited (PER AU) stock market data APIs
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company's product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory indications. Its product pipeline also includes Atesidorsen (ATL1103), an oligonucleotide targeting growth hormone receptor designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Percheron Therapeutics Limited Financial Data Overview
| 0.1 | |
| 0.1 | |
| - | |
| 0.105 | |
| 0.1 | |
| 0.052-0.11 | |
| 90 155 K | |
| 902 M | |
| 2 968 K | |
| 0.87 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Percheron Therapeutics Limited Fundamental Data is available in our Financial Data APIs
- Net Revenue 2 968 K
- EBITDA -11 900 361
- Earnings Per Share -0.01
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Percheron Therapeutics Limited Earnings via APIs
- Latest Release 2024-08-29
- EPS/Forecast NaN
Get Percheron Therapeutics Limited End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
